<DOC>
	<DOC>NCT02052986</DOC>
	<brief_summary>The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.</brief_summary>
	<brief_title>An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Adult subjects (&gt; or = 18 years of age) Enrolled in Cardiac Rehabilitation clinic with documented cardiovascular disease as assessed by the principle investigator Has had cardiovascular examination within the past 2 months Subjects who refuse to provide written consent Subjects with medical conditions, as determined by the principal investigator, which prevented them from study participation Subjects with a known bleeding or clotting disorder Subjects with known allergies to fish Subjects with an implantable cardiac defibrillator Subjects with a heart transplant Female subjects who are currently taking hormone replacement therapy Subjects who are pregnant or planning on becoming pregnant Subjects currently taking Omega3 fatty acid supplements (either under medical supervision or selfadministered)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Fatty Acids, Omega-3</keyword>
	<keyword>Omega-3 fatty acids</keyword>
	<keyword>Docosahexaenoic acid (DHA)</keyword>
	<keyword>Eicosapentaenoic acid (EPA)</keyword>
	<keyword>Docosapentaenoic acid (DPA)</keyword>
	<keyword>Omega Index</keyword>
	<keyword>Omega Score</keyword>
	<keyword>Cardiac Rehab</keyword>
</DOC>